Skip to content
10-Q

Quarterly Report

BARINTHUS BIOTHERAPEUTICS PLC BRNS

0001828185-26-000019

← back to feed
Filed
Apr 30, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · Apr 23, 2026 40.85M sh
Shares Diluted Q1 2026 · Mar 31, 2026 40.85M sh
Shares Diluted Q1 2026 · Mar 31, 2025 40.27M sh
Capex Q1 2026 · Mar 31, 2026 $0
Capex Q1 2026 · Mar 31, 2025 $5K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$3.37M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$14.9M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $65.86M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $70.46M
Stockholders Equity Q1 2026 · Mar 31, 2026 $66.4M
Stockholders Equity Q1 2026 · Dec 31, 2025 $74.21M
Current Liabilities Q1 2026 · Mar 31, 2026 $12M
Current Liabilities Q1 2026 · Dec 31, 2025 $10.02M
Total Liabilities Q1 2026 · Mar 31, 2026 $25.67M
Total Liabilities Q1 2026 · Dec 31, 2025 $23.88M
Current Assets Q1 2026 · Mar 31, 2026 $72.66M
Current Assets Q1 2026 · Dec 31, 2025 $77.79M
Total Assets Q1 2026 · Mar 31, 2026 $92.14M
Total Assets Q1 2026 · Dec 31, 2025 $98.17M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.14
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.49
Eps Basic Q1 2026 · Mar 31, 2026 −$0.14
Eps Basic Q1 2026 · Mar 31, 2025 −$0.49
Sga Expense Q1 2026 · Mar 31, 2026 $2.53M
Sga Expense Q1 2026 · Mar 31, 2025 $12.64M
Rd Expense Q1 2026 · Mar 31, 2026 $3.59M
Rd Expense Q1 2026 · Mar 31, 2025 $8.29M
Net Income Q1 2026 · Mar 31, 2026 −$5.53M
Net Income Q1 2026 · Mar 31, 2025 −$19.65M
Operating Income Q1 2026 · Mar 31, 2026 −$6.08M
Operating Income Q1 2026 · Mar 31, 2025 −$20.6M